Skip to main content

01-01-2015 | Gastric cancer | Book chapter | Article

11. Gastric Cancer: Molecular Mechanisms, Diagnosis, and Treatment

Authors: M.D. Gopi K. Prithviraj, M.D., M.P.H. Khaldoun Almhanna

Publisher: Springer International Publishing


Gastric cancer is one of the most frequently diagnosed cancers worldwide, with a relative 5 year survival of 27.7 %. The clinical outcome for advanced gastric cancer remains poor, with 5-year relative survival of only 3.9 %. Many risk factors have been identified in relation to gastric cancer, including Helicobacter pylori, Epstein-Barr virus infection, family history of gastric cancer, and the presence of pathologic changes such as atrophic gastritis, intestinal metaplasia, and high-grade dysplasia. At this time, the current standard of care in the first-line treatment of advanced or metastatic gastric cancer includes a platinum plus fluoropyrimidine backbone, while the primary treatment of early stage disease is resection with consideration for neoadjuvant, perioperative, or adjuvant chemotherapy. While early-stage gastric cancers may be successfully treated with surgical and medical therapy, metastatic gastric cancer continues to have a limited overall survival despite treatment. Herein we discuss the pathogenesis, screening, diagnosis, and treatment of gastric cancer, including future directions such as targeted therapies.

Please log in to get access to this content

Related topics